Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Non-cash Items (2021 - 2024)

Historic Non-cash Items for Treace Medical Concepts (TMCI) over the last 4 years, with Q4 2024 value amounting to $5.5 million.

  • Treace Medical Concepts' Non-cash Items rose 2060.44% to $5.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.5 million, marking a year-over-year increase of 2060.44%. This contributed to the annual value of $5.5 million for FY2024, which is 2060.44% up from last year.
  • Per Treace Medical Concepts' latest filing, its Non-cash Items stood at $5.5 million for Q4 2024, which was up 2060.44% from $4.6 million recorded in Q4 2023.
  • In the past 5 years, Treace Medical Concepts' Non-cash Items registered a high of $12.8 million during Q4 2022, and its lowest value of $3.7 million during Q4 2021.
  • For the 4-year period, Treace Medical Concepts' Non-cash Items averaged around $6.0 million, with its median value being $4.7 million (2021).
  • As far as peak fluctuations go, Treace Medical Concepts' Non-cash Items soared by 24338.06% in 2022, and later tumbled by 6411.94% in 2023.
  • Over the past 4 years, Treace Medical Concepts' Non-cash Items (Quarter) stood at $3.7 million in 2021, then skyrocketed by 243.38% to $12.8 million in 2022, then plummeted by 64.12% to $4.6 million in 2023, then increased by 20.6% to $5.5 million in 2024.
  • Its last three reported values are $5.5 million in Q4 2024, $4.6 million for Q4 2023, and $12.8 million during Q4 2022.